PureTech Health (NASDAQ:PRTC) Shares Gap Down to $25.78

Shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) gapped down before the market opened on Thursday . The stock had previously closed at $25.78, but opened at $23.52. PureTech Health shares last traded at $23.52, with a volume of 5 shares trading hands.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on PRTC shares. Piper Sandler set a $37.00 price target on shares of PureTech Health in a report on Monday, June 20th. SVB Leerink decreased their price target on shares of PureTech Health from $70.00 to $66.00 and set an “outperform” rating for the company in a report on Wednesday, June 15th.

PureTech Health Price Performance

The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 0.02. The stock’s fifty day simple moving average is $22.42 and its 200-day simple moving average is $26.32.

About PureTech Health

(Get Rating)

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.